Advocacy | Association for Accessible Medicines
Welcome Message - Blog from AAM President and CEO Dan Leonard: Generics: The Bridge to A Vaccine.

Advocacy

We Advocate

When patients and voters like you speak up on health care issues, you make it possible for millions of Americans to experience savings at the pharmacy counter and to lead healthier and more productive lives.

A Sustainable Supply Chain

Developers of generic and biosimilar medicines support diversification of the pharmaceutical supply chain and working with policymakers on measures to make it feasible to bring more manufacturing back to the United States.

Biosimilars

Biosimilars have the potential to improve the quality of life for patients while at the same time saving the health system billions of dollars each year.

Intellectual Property & Patent Reform

AAM opposes abuses of the patent system by brand-name drug companies, and we advocate for patent reform that lends itself to timely patient access to safe, effective and more-affordable medicines for patients in the United States.

Medicaid Generics Penalty

Unless it is repealed, the Medicaid Generics Penalty could destabilize the robust market for generic drugs and impede patient access to affordable, lifesaving drugs.

State Legislation

AAM works with federal and state level governments to promote best practices aimed at increasing the use of generic medicines and saving taxpayer money. These efforts include rapid responses to anti-substitution stories, advocating for specific generic substitution laws and general education.

Trade

AAM promotes and protects access to affordable medicines in trade agreements and represents these interests before the U.S. Trade Representative, the Department of Commerce, Congress, The White House and other stakeholders.

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.